MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Surmodics Interest Expense 2011-2026 | SRDX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 310 K | 133 K | 152 K | - | - | - | 496 K | 133 K | 137 K | 228 K | 401 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 496 K | 133 K | 249 K |
Quarterly Interest Expense Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 879 K | 881 K | 896 K | - | 884 K | 884 K | 826 K | - | 145 K | 129 K | 136 K | - | 59 K | 59 K | 60 K | 99 K | 29 K | 60 K | 40 K | 112 K | 38 K | 40 K | 37 K | - | - | 37 K | - | - | - | - | - | - | -6 K | 361 K | - | 496 K | -40 K | 543 K | -7 K | 125 K | 125 K | -7 K | - | 1.34 M | 2 K | 163 K | 1.18 M | 172 K | 2 K | 162 K | 8 K | 379 K | 171 K | 8 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.34 M | -40 K | 281 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
-1.45 M | $ 8.91 | 0.51 % | $ 594 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 25.85 | 0.08 % | $ 718 M | USA |
 |
DexCom
DXCM
|
177 M | $ 67.92 | 2.38 % | $ 26.5 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 157.08 | 3.45 % | $ 7.79 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.51 | 1.07 % | $ 933 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.81 | -0.04 % | $ 19.6 B | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 87.36 | 0.2 % | $ 11 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.45 | 3.34 % | $ 467 M | USA |
|
Biodesix
BDSX
|
8.26 M | $ 17.14 | -0.87 % | $ 2.22 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 100.87 | 3.33 % | $ 8.32 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.86 | 0.7 % | $ 92.8 K | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 170.64 | 3.54 % | $ 29.3 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 196.09 | 2.46 % | $ 140 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 120.51 | 1.03 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 199.89 | 0.48 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
81 M | $ 114.44 | 2.33 % | $ 34.8 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.11 | -0.45 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 8.74 | 3.8 % | $ 248 M |  Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.31 | 2.2 % | $ 2.02 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 78.85 | 0.45 % | $ 5.32 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.39 | 1.84 % | $ 417 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 461.07 | 1.64 % | $ 13.3 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 224.83 | 2.14 % | $ 25.2 B |  Schweiz |
 |
Celcuity
CELC
|
2.11 M | $ 113.19 | -1.49 % | $ 4.47 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 18.02 | 3.56 % | $ 403 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.4 | 2.0 % | $ 1.08 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
9.32 M | $ 201.85 | 2.11 % | $ 19.9 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.2 | 0.84 % | $ 833 M | USA |